Advertisement


Mario E. Lacouture, MD, on Management of Dermatologic Toxicities Associated With Targeted Therapies

2015 NCCN Annual Conference

Advertisement

Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocial impact, financial burden, physiological pain, and potential to alter therapy. But the side effects of targeted treatments can and should be addressed.



Related Videos

Issues in Oncology

Mary Lou Smith, JD, MBA, on the Value of NCCN Guidelines to Patients and Their Advocates

Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on ...

Cost of Care

Clifford Goodman, PhD, and Peter B. Bach, MD, MAPP, on Value-Based Decision-Making at the Bedside

Clifford Goodman, PhD, of the The Lewin Group, and Peter B. Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center, discuss the affordability of cancer care, th...

Peter G. Shields, MD, on New NCCN Guidelines: Smoking Cessation for Patients With Cancer

Peter G. Shields, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the new NCCN Guidelines for he...

Leukemia

William G. Wierda, MD, PhD, on Updates to the Management of CLL

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the latest information on managing CLL and his optimism that a cure is in sight.

Robert W. Carlson, MD, and John A. Gentile, Jr, on Milestones of NCCN

Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and John A. Gentile, Jr, Chairman, Harborside Press, LLC, discuss the early ...

Advertisement

Advertisement



Advertisement